---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-26-022088"
form_type: "8-K"
ticker: "MBRX"
cik: "0001659617"
company_name: "Moleculin Biotech, Inc."
filed_at: "2026-06-30T12:30:18+00:00"
generated_at: "2026-06-30T12:35:16.003087+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Moleculin reports Annamycin CR rates 3x control in Phase 2/3 MIRACLE interim

## Summary
- CR of 43% and 36% for Annamycin arms vs 12% control; CRc 50% and 57% vs 29% control (n=45, ITT).
- iDMC unanimously recommended continuing; no statistical significance at interim per O'Brien-Fleming design.
- Part A enrollment 67 of 90 (74%); trial remains powered at 80% for final analysis of ~282 subjects.
- Results after single cycle; 75.6% of patients over 60, 31.1% pretreated with venetoclax.

## SEC filing metadata
- accession: 0001437749-26-022088
- form_type: 8-K
- ticker: MBRX
- cik: 0001659617
- company_name: Moleculin Biotech, Inc.
- filed_at: 2026-06-30T12:30:18+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1659617/000143774926022088/0001437749-26-022088-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1659617/000143774926022088/mbrx20260630_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-26-022088
- JSON: https://secwatch.observer/filing/0001437749-26-022088.json
- Plain text: https://secwatch.observer/filing/0001437749-26-022088.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.